LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab (Avastin) to first-line chemotherapy, while patients without high risk did not ...

The Food and Drug Administration (FDA) has approved Jobevne ™ (bevacizumab-nwgd), a biosimilar to Avastin ® (bevacizumab). Jobevne is a vascular endothelial growth factor inhibitor indicated ...

The Food and Drug Administration (FDA) has approved Jobevne ™ (bevacizumab-nwgd), a biosimilar to Avastin ® (bevacizumab). Jobevne is a vascular endothelial growth factor inhibitor indicated ...

A total of 1,401 patients were randomly assigned in this 2 × 2 analysis. Median progression-free survival (PFS) was 9.4 months in the bevacizumab group and 8.0 months in the placebo group (hazard ...

Enzene’s launch of bevacizumab comes a month after its biosimilar version of cetuximab (Merck’s head and neck cancer drug) was launched by Alkem Oncology. One more product is said to be in the ...

Bevacizumab targets VEGF – a growth factor that can promote tumor angiogenesis in ovarian cancer - blocking its effects and reducing tumor growth. Of relevance, is the role bevacizumab may play in ...

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with ...

Alymsys ® (bevacizumab-maly), a biosimilar to Avastin ® (bevacizumab), has been made available by Amneal Pharmaceuticals. Alymsys is a vascular endothelial growth factor inhibitor indicated for ...